BioNTech SE

BNTX

NASDAQ. Currency in USD

170.30 -1.51 ( -0.88% )

Real time prices: December 09

Market Cap.
41.33B
Beta (5Y monthly)
0.16
Price/Earnings
3.83
EPS (TTM)
44.26
Forward Dividend
2.11 (1.30%)
Ex-Dividend Date
Jun 03, 2022
Volume
817,468
1y Target Est.
215.61
Day's Range
169.29
-
173.00
52 Week's Range
117.08
-
302.34

Historical Summary

Performance
EPS growth
Share Buybacks

About BioNTech SE

Sector
Healthcare
Industry
Biotechnology
Website
https://www.biontech.de
Exchange
NASDAQ (XNAS)
Shares Outstanding
246.81M
Employees
4000
Address
An der Goldgrube 12, Mainz, Germany, 55131
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Latest news

BioNTech und Ryvu Therapeutics schließen  globale Kollaboration zur Entwicklung und Vermarktung  von immunmodulierenden niedermolekularen Wirkstoffen
BioNTech und Ryvu Therapeutics schließen globale Kollaboration zur Entwicklung und Vermarktung von immunmodulierenden niedermolekularen Wirkstoffen

MAINZ, Deutschland und KRAKAU, Polen, 30. November 2022 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX,...
By GlobeNewswire Inc. - 1 week ago

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

MAINZ, Germany and KRAKOW, Poland – November 30, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”)...
By GlobeNewswire Inc. - 1 week ago

IMF head joins chorus calling on China to adapt COVID strategy as officials pledge to boost vaccinations among elderly
IMF head joins chorus calling on China to adapt COVID strategy as officials pledge to boost vaccinations among elderly

The head of the International Monetary Fund on Tuesday joined the chorus of people urging...
By MarketWatch - 1 week ago

IMF head joins chorus calling on China to adapt COVID strategy as officials pledge to boost vaccinations among elderly
IMF head joins chorus calling on China to adapt COVID strategy as officials pledge to boost vaccinations among elderly

The head of the International Monetary Fund on Tuesday joined the chorus of people urging...
By MarketWatch - 1 week ago

BioNTech SE Sponsored ADR (BNTX) Just Overtook the 20-Day Moving Average
BioNTech SE Sponsored ADR (BNTX) Just Overtook the 20-Day Moving Average

Good things could be on the horizon when a stock surpasses the 20-day simple moving...
By Zacks Investment Research - 1 week ago

China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says  Fauci
China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says Fauci

Widespread protests across China over the government's zero-COVID policy dominated headlines on the pandemic on...
By MarketWatch - 1 week ago

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why
Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine...
By Zacks Investment Research - 1 week ago

China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says  Fauci
China’s zero-COVID strategy makes no sense and its homegrown vaccines are not ‘particularly effective,’ says Fauci

Widespread protests across China over the government's zero-COVID policy dominated headlines on the pandemic on...
By MarketWatch - 1 week ago